Latest European Market Access News

Osmond Resources has reinforced the continuity of high-grade critical minerals at its Orión project in Spain, with drill hole SOR-07A delivering promising assay results. The company is on track to release its maiden Mineral Resource Estimate and Scoping Study by Q3 2026, supported by robust mineral processing testwork and a new Frankfurt listing.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Provaris Energy, alongside Kawasaki Kisen Kaisha (K LINE) and Norwegian Hydrogen, has formalised a cooperation to develop a commercial hydrogen shipping supply chain from Norway to Northern Europe, focusing on cost modelling and charter terms for compressed hydrogen transport.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Altech Batteries, in partnership with AMPower, has launched a next-generation 384 V / 15 kWh sodium nickel chloride UPS battery designed specifically for Europe's pipeline infrastructure, promising enhanced safety and reliability in explosive environments.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.